Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Circle Pharma Inc.
Headquarters: San Francisco, CA, United States of America
Website: http://www.circlepharma.com/...
Year Founded: 2013
Status: Private
BioCentury | Feb 13, 2025
Emerging Company Profile
Unnatural: Expanding the macrocyclic peptide chemical space
Company applying small molecule optimization techniques to peptides with a robotic synthesis platform
BioCentury | Oct 15, 2024
Deals
Three new partnerships that could be worth over $1B
Deals report: Astellas-AviadoBio in CNS gene therapy deal, Merck-Mestag to identify inflammatory targets, Eli Lilly-KeyBioscience tackling obesity
BioCentury | Sep 17, 2024
Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
BioCentury | Sep 7, 2022
Emerging Company Profile
IPD spinout Vilya computing new paths to oral macrocycle therapies
Vilya is putting the Baker lab’s protein design tools to work finding oral compounds that can target intracellular protein-protein interactions
BioCentury | Jul 27, 2022
Management Tracks
Two River, Merck alum Snyder joins Generate as CMO
Plus Nagorse becomes CMO at Affini-T and updates from Apollomics, Circle and more
BioCentury | Jun 17, 2021
Finance
June 17 Quick Takes: Trio of IPOs for Verve, Lyell and CARSgen; plus Biogen, Shoreline-Kite, Zhaoke-PanOptica and more
Despite waning enthusiasm for biotech IPOs, cardiovascular gene editing play Verve Therapeutics Inc. (NASDAQ:VERV) jumped $12.92 (68%) to $31.92 on its first day of trading Thursday after raising
BioCentury | May 14, 2021
Emerging Company Profile
Nine Square: taking aim at organelle function in movement disorders with computation and imaging
The Apple Tree-founded UCSF spinout is developing CNS-targeted small molecules against genetically defined targets
BioCentury | Jul 22, 2020
Management Tracks
Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more
Items per page:
1 - 10 of 15